EXOSOME-BASED LIQUID BIOPSY
Craif is a pioneer in exosome-based liquid biopsy for accurate and unpainful early cancer detection.
We aim to create a society where everyone can stay healthy throughout their lifetime.
Craif was featured in the CRDS research report as a major biotech venture in Japan.
Craif CTO, Dr. Ichikawa, made a presentation at the 81st Discussion Session of the Japan Society for Analytical Chemistry.
Craif present results of urine-based urothelial cancer detection at the American Association of Cancer Research (AACR) Annual Meeting 2021
Craif Inc. Announces Residency at JLABS @ Shanghai To Further Accelerate the Development of an Innovative Exosome Biomarker Discovery Platform
Enrichment of exosomes from body fluid efficiently with a simple procedure allows a more accurate interpretation of cellular communications